Previous 10 | Next 10 |
Sorrento Therapeutics (SRNE) has completed enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure ((ARD)) or acute respiratory distress syndrome ((ARDS)).This current study (MSC-COV-1...
The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished. All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion. No infusion-related adverse events were observed. Sorrento plans a p...
Sorrento Therapeutics will acquire ACEA Therapeutics in a deal worth up to $488 million. Sorrento will pay $38 million upfront in stock and make up to an additional $450 million in milestones payments. Beijing's BeiGene was approved to manufacture the company's approved anti-PD-1 anti...
Sorrento Therapeutics recently announced the acquisition of ACEA Therapeutics. ACEA's acquisition brings to Sorrento the late clinical-stage Abivertinib. The company received a supplemental new drug application approval from FDA for its lidocaine topical system ZTlido. For f...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE). On May 15, 2020, news sources reporte...
Sorrento Therapeutics (SRNE) has filed to sell ~851K shares from selling shareholder Icahn School of Medicine at Mount Sinai.The proposed aggregate maximum offering price is ~$6.47M.Last month, Mount Sinai licensed to Sorrento antibodies that could be used as SARS-CoV-2 treatment.Sorrento sha...
Scilex Holding, an over 99% owned subsidiary of Sorrento Therapeutics ([[SRNE]] -2.8%), has received a supplemental new drug application ((sNDA)) approval from the U.S. FDA for ZTlido to make efficacy labeling change with clinical data.ZTlido (lidocaine patch) 1.8% is indicated for the t...
PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to ma...
Sorrento Therapeutics (SRNE) has agreed to acquire ACEA Therapeutics in return for $38M of its common stock.The milestone payments could add up to $450M in additional payments subject to certain adjustments per the merger agreement.Sorrento will also pay ACEA equity holders 5 – 10% of ...
ACEA’s major assets include: Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell lymphoma study, and ongoing Phase 2 trials in COVID-19 patients with ARDS, and Pha...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...